|
1
|
Strumylaite L, Kregzdyte R, Kucikiene O, Baranauskiene D, Simakauskiene V, Naginiene R, Damuleviciene G, Lesauskaite V, Zemaitiene R. Alzheimer's Disease Association with Metals and Metalloids Concentration in Blood and Urine. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:ijerph19127309. [PMID: 35742553 PMCID: PMC9224238 DOI: 10.3390/ijerph19127309] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 06/10/2022] [Accepted: 06/11/2022] [Indexed: 02/01/2023]
Abstract
As there is some evidence that the risk for Alzheimer’s disease (AD) is partially attributable to environmental exposure to some metals and metalloids, we examined an association between AD and arsenic, chromium, and selenium in 53 AD patients and 217 controls. Urinary arsenic, blood chromium, and selenium were determined by inductively coupled plasma mass spectrometry. Logistic regression models calculating odds ratios (ORs) and 95% confidence intervals (CI) were used to estimate AD association with arsenic, chromium, and selenium. In AD patients, urinary arsenic and blood chromium were significantly higher, while blood selenium was significantly lower compared to controls. Increased blood selenium was related to a significant decrease in the odds of AD after adjustment for risk factors. Blood selenium per 1 kg × 10−9/m3 × 10−4 increment was associated with 1.4 times lower risk of AD (OR = 0.71; 95% CI 0.58–0.87). A significant increase in the odds of AD associated with increased blood chromium was also seen in the adjusted model: the OR per 1 kg × 10−9/m3 × 10−3 chromium increment was 2.39 (95% CI 1.32–4.31). The association of urinary arsenic with the risk of AD was not significant. The data obtained provide evidence that selenium reduces the risk of Alzheimer’s disease, while chromium increases it.
Collapse
Affiliation(s)
- Loreta Strumylaite
- Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (R.K.); (D.B.); (V.S.); (R.N.)
- Correspondence: ; Tel.: +370-37-302948
| | - Rima Kregzdyte
- Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (R.K.); (D.B.); (V.S.); (R.N.)
| | - Odeta Kucikiene
- Department of Geriatrics, Medical Academy, Lithuanian University of Health Science, LT-44307 Kaunas, Lithuania; (O.K.); (G.D.); (V.L.)
| | - Dale Baranauskiene
- Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (R.K.); (D.B.); (V.S.); (R.N.)
| | - Vaida Simakauskiene
- Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (R.K.); (D.B.); (V.S.); (R.N.)
| | - Rima Naginiene
- Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (R.K.); (D.B.); (V.S.); (R.N.)
| | - Gyte Damuleviciene
- Department of Geriatrics, Medical Academy, Lithuanian University of Health Science, LT-44307 Kaunas, Lithuania; (O.K.); (G.D.); (V.L.)
| | - Vita Lesauskaite
- Department of Geriatrics, Medical Academy, Lithuanian University of Health Science, LT-44307 Kaunas, Lithuania; (O.K.); (G.D.); (V.L.)
| | - Reda Zemaitiene
- Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania;
| |
Collapse
|